Swiss National Bank Buys 9,400 Shares of Humacyte, Inc. (NASDAQ:HUMA)

Swiss National Bank boosted its stake in Humacyte, Inc. (NASDAQ:HUMA) by 5.8% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 172,100 shares of the company’s stock after acquiring an additional 9,400 shares during the period. Swiss National Bank owned 0.14% of Humacyte worth $869,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. HighTower Advisors LLC purchased a new stake in shares of Humacyte during the 4th quarter worth approximately $66,000. Endowment Wealth Management Inc. raised its stake in shares of Humacyte by 3.6% in the fourth quarter. Endowment Wealth Management Inc. now owns 104,108 shares of the company’s stock valued at $526,000 after buying an additional 3,590 shares during the period. Raymond James Financial Inc. purchased a new position in shares of Humacyte during the 4th quarter valued at $377,000. Charles Schwab Investment Management Inc. grew its stake in shares of Humacyte by 7.5% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 775,718 shares of the company’s stock worth $3,917,000 after acquiring an additional 54,400 shares during the period. Finally, Rowlandmiller & PARTNERS.ADV purchased a new stake in Humacyte in the 4th quarter worth about $159,000. 44.71% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

HUMA has been the topic of several recent research reports. D. Boral Capital reaffirmed a “buy” rating and set a $25.00 price objective on shares of Humacyte in a report on Wednesday. Benchmark reaffirmed a “buy” rating on shares of Humacyte in a report on Thursday, February 27th. Finally, HC Wainwright reissued a “buy” rating and set a $15.00 target price on shares of Humacyte in a report on Wednesday, March 12th. One investment analyst has rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Buy” and an average target price of $13.71.

Humacyte Trading Down 2.5 %

Humacyte stock opened at $1.96 on Friday. The firm’s 50 day simple moving average is $3.61 and its 200 day simple moving average is $4.50. Humacyte, Inc. has a 1-year low of $1.76 and a 1-year high of $9.97. The firm has a market capitalization of $246.68 million, a PE ratio of -1.46 and a beta of 1.36.

Humacyte (NASDAQ:HUMA) last released its quarterly earnings results on Friday, March 28th. The company reported ($0.16) earnings per share for the quarter, topping the consensus estimate of ($0.23) by $0.07. Research analysts forecast that Humacyte, Inc. will post -1.27 earnings per share for the current year.

Humacyte Company Profile

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.